FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2394328144> ?p ?o ?g. }

• W2394328144 endingPage "360" @default.
• W2394328144 startingPage "355" @default.
• W2394328144 abstract "No AccessJournal of UrologyAdult Urology1 Aug 2016Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer Donna Pauler Ankerst, Jonathan Gelfond, Martin Goros, Jesus Herrera, Andreas Strobl, Ian M. Thompson, Javier Hernandez, and Robin J. Leach Donna Pauler AnkerstDonna Pauler Ankerst Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Department of Mathematics, Technische Universitaet Muenchen, Munich, Germany More articles by this author , Jonathan GelfondJonathan Gelfond Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author , Martin GorosMartin Goros Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author , Jesus HerreraJesus Herrera Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author , Andreas StroblAndreas Strobl Department of Mathematics, Technische Universitaet Muenchen, Munich, Germany More articles by this author , Ian M. ThompsonIan M. Thompson Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author , Javier HernandezJavier Hernandez Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author , and Robin J. LeachRobin J. Leach Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.03.011AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We characterized the diagnostic properties of serial percent free prostate specific antigen in relation to prostate specific antigen in a multiethnic, multiracial cohort of healthy men. Materials and Methods: A total of 6,982 percent free prostate specific antigen and prostate specific antigen measurements were obtained from participants in a greater than 12-year Texas screening study comprising 1,625 men who never underwent biopsy, 497 who underwent 1 or more biopsies negative for prostate cancer and 61 diagnosed with prostate cancer. We evaluated the ROC AUC of percent free prostate specific antigen and the proportion of patients with fluctuating values across multiple visits determined according to 2 thresholds (less than 15% vs 25%). The proportion of cancer cases in which percent free prostate specific antigen indicated a positive test before prostate specific antigen greater than 4 ng/ml did and the number of negative biopsies that would have been spared by negative percent free prostate specific antigen test results were calculated. Results: Percent free prostate specific antigen fluctuated around its threshold of less than 25% (less than 15%) in 38.3% (78.1%), 42.2% (20.9%), and 11.4% (25.7%) of patients never biopsied, and with negative and positive biopsies, respectively. At the same thresholds, percent free prostate specific antigen tested positive earlier than prostate specific antigen in 71.4% and 34.2% of cancer cases, respectively. Among men with multiple negative biopsies and PSA greater than 4 ng/ml, percent free PSA would have tested negative in 31.6% and 65.8%, respectively. Conclusions: Percent free prostate specific antigen should accompany prostate specific antigen testing to potentially spare unnecessary biopsies or detect cancer earlier. When near the threshold, both tests should be repeated due to commonly observed fluctuation. References 1 : Screening for prostate cancer. Preventive Services Task Force recommendation statement. Ann Intern Med2012; 157: 120. Google Scholar 2 : Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ2014; 348: g2296. Google Scholar 3 : Baseline prostate-specific antigen testing at a young age. Eur Urol2012; 61: 1. Google Scholar 4 : Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA2003; 289: 2695. Google Scholar 5 : Yearly prostate specific and digital rectal examination fluctuations in a screened population. J Urol2009; 181: 2071. Link, Google Scholar 6 : Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?. Cancer Epdemiol Biomarkers Prev2004; 13: 1640. Google Scholar 7 : Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with “gray” prostate-specific antigen levels at first biopsy: systematic review and meta-analysis. Transl Res2014; 164: 444. Google Scholar 8 : Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol2013; 63: 986. Google Scholar 9 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Crossref, Medline, Google Scholar 10 : Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol2011; 185: 104. Link, Google Scholar 11 : Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology2014; 83: 1362. Google Scholar 12 : Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA2015; 314: 2054. Google Scholar 13 : National prostate cancer screening rates after the 2012 US Preventive services task force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol2015; 33: 2416. Google Scholar 14 Beck M: Doctors Could be Penalized for Ordering Prostate Tests. Wall Street Journal, November 19, 2015. Available at http://www.wsj.com/articles/doctors-could-be-penalized-for-ordering-prostate-tests-1447993920. Accessed November 19, 2015. Google Scholar 15 : Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol2010; 28: 1117. Google Scholar 16 : Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst2006; 98: 529. Google Scholar 17 : Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA2014; 312: 995. Google Scholar 18 : Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012; 104: 125. Google Scholar 19 : Long-term survival of participants in the Prostate Cancer Prevention Trial. N Engl J Med2013; 369: 603. Google Scholar 20 : Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology2001; 58: 561. Google Scholar 21 : Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. BJU Int2011; 107: 1769. Google Scholar 22 : Intraindividual variation in total and percent free prostate-specific antigen levels in prostate cancer suspects. Urol Int2004; 74: 198. Google Scholar 23 : Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol1997; 157: 2179. Link, Google Scholar 24 : Variation of free and total prostate-specific antigen levels: the effect on the percent free/total prostate-specific antigen. Arch Pathol Lab Med1997; 121: 385. Google Scholar 25 : Intraindividual variations of total and percent free serum prostatic-specific antigen levels in patients with normal digital rectal examination. Eur Urol1999; 36: 111. Google Scholar © 2016 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 196Issue 2August 2016Page: 355-360Supplementary Materials Advertisement Copyright & Permissions© 2016 by American Urological Association Education and Research, Inc.Keywordsmass screeningdiagnosisprostatic neoplasmsprostate-specific antigenbiopsyMetricsAuthor Information Donna Pauler Ankerst Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Department of Mathematics, Technische Universitaet Muenchen, Munich, Germany More articles by this author Jonathan Gelfond Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Martin Goros Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Jesus Herrera Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Andreas Strobl Department of Mathematics, Technische Universitaet Muenchen, Munich, Germany More articles by this author Ian M. Thompson Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Javier Hernandez Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Robin J. Leach Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2394328144 created "2016-06-24" @default.
• W2394328144 creator A5009108510 @default.
• W2394328144 creator A5015887484 @default.
• W2394328144 creator A5024582072 @default.
• W2394328144 creator A5048506409 @default.
• W2394328144 creator A5056530679 @default.
• W2394328144 creator A5061399098 @default.
• W2394328144 creator A5068893673 @default.
• W2394328144 creator A5078370671 @default.
• W2394328144 date "2016-08-01" @default.
• W2394328144 modified "2023-09-26" @default.
• W2394328144 title "Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer" @default.
• W2394328144 cites W1895340590 @default.
• W2394328144 cites W1964223543 @default.
• W2394328144 cites W1966857251 @default.
• W2394328144 cites W1982747940 @default.
• W2394328144 cites W1994381348 @default.
• W2394328144 cites W2012608816 @default.
• W2394328144 cites W2020781934 @default.
• W2394328144 cites W2022688975 @default.
• W2394328144 cites W2032359663 @default.
• W2394328144 cites W2055228524 @default.
• W2394328144 cites W2089378422 @default.
• W2394328144 cites W2092393899 @default.
• W2394328144 cites W2094324071 @default.
• W2394328144 cites W2106519742 @default.
• W2394328144 cites W2117599049 @default.
• W2394328144 cites W2134793522 @default.
• W2394328144 cites W2134967293 @default.
• W2394328144 cites W2139566281 @default.
• W2394328144 cites W2160217483 @default.
• W2394328144 cites W2165416035 @default.
• W2394328144 cites W2166503668 @default.
• W2394328144 cites W2171655721 @default.
• W2394328144 cites W2175023894 @default.
• W2394328144 cites W2412258266 @default.
• W2394328144 doi "https://doi.org/10.1016/j.juro.2016.03.011" @default.
• W2394328144 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4969186" @default.
• W2394328144 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26979652" @default.
• W2394328144 hasPublicationYear "2016" @default.
• W2394328144 type Work @default.
• W2394328144 sameAs 2394328144 @default.
• W2394328144 citedByCount "26" @default.
• W2394328144 countsByYear W23943281442017 @default.
• W2394328144 countsByYear W23943281442018 @default.
• W2394328144 countsByYear W23943281442019 @default.
• W2394328144 countsByYear W23943281442020 @default.
• W2394328144 countsByYear W23943281442021 @default.
• W2394328144 countsByYear W23943281442022 @default.
• W2394328144 crossrefType "journal-article" @default.
• W2394328144 hasAuthorship W2394328144A5009108510 @default.
• W2394328144 hasAuthorship W2394328144A5015887484 @default.
• W2394328144 hasAuthorship W2394328144A5024582072 @default.
• W2394328144 hasAuthorship W2394328144A5048506409 @default.
• W2394328144 hasAuthorship W2394328144A5056530679 @default.
• W2394328144 hasAuthorship W2394328144A5061399098 @default.
• W2394328144 hasAuthorship W2394328144A5068893673 @default.
• W2394328144 hasAuthorship W2394328144A5078370671 @default.
• W2394328144 hasBestOaLocation W23943281442 @default.
• W2394328144 hasConcept C121608353 @default.
• W2394328144 hasConcept C126322002 @default.
• W2394328144 hasConcept C126894567 @default.
• W2394328144 hasConcept C143998085 @default.
• W2394328144 hasConcept C147483822 @default.
• W2394328144 hasConcept C203014093 @default.
• W2394328144 hasConcept C2776235491 @default.
• W2394328144 hasConcept C2780192828 @default.
• W2394328144 hasConcept C2781406297 @default.
• W2394328144 hasConcept C2908647359 @default.
• W2394328144 hasConcept C71924100 @default.
• W2394328144 hasConcept C87874733 @default.
• W2394328144 hasConcept C99454951 @default.
• W2394328144 hasConceptScore W2394328144C121608353 @default.
• W2394328144 hasConceptScore W2394328144C126322002 @default.
• W2394328144 hasConceptScore W2394328144C126894567 @default.
• W2394328144 hasConceptScore W2394328144C143998085 @default.
• W2394328144 hasConceptScore W2394328144C147483822 @default.
• W2394328144 hasConceptScore W2394328144C203014093 @default.
• W2394328144 hasConceptScore W2394328144C2776235491 @default.
• W2394328144 hasConceptScore W2394328144C2780192828 @default.
• W2394328144 hasConceptScore W2394328144C2781406297 @default.
• W2394328144 hasConceptScore W2394328144C2908647359 @default.
• W2394328144 hasConceptScore W2394328144C71924100 @default.
• W2394328144 hasConceptScore W2394328144C87874733 @default.
• W2394328144 hasConceptScore W2394328144C99454951 @default.
• W2394328144 hasIssue "2" @default.
• W2394328144 hasLocation W23943281441 @default.
• W2394328144 hasLocation W23943281442 @default.
• W2394328144 hasLocation W23943281443 @default.
• W2394328144 hasLocation W23943281444 @default.
• W2394328144 hasOpenAccess W2394328144 @default.
• W2394328144 hasPrimaryLocation W23943281441 @default.
• W2394328144 hasRelatedWork W1992657261 @default.
• W2394328144 hasRelatedWork W2038565121 @default.
• W2394328144 hasRelatedWork W2148869351 @default.
• W2394328144 hasRelatedWork W2354678759 @default.
• W2394328144 hasRelatedWork W2373651588 @default.

• next